Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.
Peripartum cardiomyopathy (PPCM) is a rare disease of unclear etiology with a frequent poor outcome, despite optimal medical therapy. Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure.
Jahns
Boriana G
BG
Department of Gynecology and Obstetrics, Georg-August-University, Göttingen, Germany. boriana_jahns@yahoo.com
Stein
Werner
W
Hilfiker-Kleiner
Denise
D
Pieske
Burkert
B
Emons
Günter
G
D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000378:metabolism; D002402:Cathepsin D / Q000378:metabolism; D005260:Female; D017359:HELLP Syndrome; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006727:Hormone Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009206:Myocardium / Q000378:metabolism; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000378:metabolism; D011388:Prolactin / Q000037:antagonists & inhibitors
D006727:Hormone Antagonists; D001971:Bromocriptine; D011388:Prolactin; D002402:Cathepsin D